Fosun Pharma Sells Ex-China Rights for Two Drug Candidates in $531 Million Deal
Published: Oct 22, 2013
by Richard Daverman, PhD
October 21, 2013 -- In a blockbuster deal, Shanghai Fosun Pharma plans to sell ex-China rights for two drug candidates – one treating cancer, the other diabetes – to Sellas Clinicals Holding of Switzerland. Sellas will pay up to $531.4 million in clinical milestones, based on trials in the US and Europe. The agreement, which has not been finalized, will be between an indirect subsidiary of Fosun, Chongqing Fochon Pharma, and Sellas. More details....
Stock Symbol: (SHA: 600196; HK: 02196)
Help employers find you! Check out all the jobs and post your resume.